資源描述：
《晚期非小細(xì)胞肺癌化療療效分析與化療敏感性預(yù)測(cè)》由會(huì)員上傳分享，免費(fèi)在線閱讀，更多相關(guān)內(nèi)容在教育資源-天天文庫。
1、第三軍醫(yī)大學(xué)碩士學(xué)位論文Kaplan-Meiersurvivalanalysesandlog-ranktest．9．q,c—MIBlwereperformedin19advancedNSCLCpatientswithinaweekofpre-chemotherapy，earlyimageanddelayimageweretookin20rainand150rain,respectively．Then,theywerechosetobegivenregimensofTP、GP、NP、DP．c—MIBISPECTqua
2、litativeanalysiswasdiagnosedbymorethantwonuclearmedicinetechnologists，radioactiveconcentrationisdeterminationcriteria．Quantitativeanalysisbasedon99rnTc-MIBIuptakebytumor．Usingaratiooftheaveragecountsinthelesiontothoseinthecontralateralnormalregionontheearly(T／
3、Ne)anddelayed(T／Nd)SPECTimagesandretentionindexfROdefinedasthepercentageofchangein帥rc-1訂mIuptake，Wascalculatedusing【(T／Nd-T廠Ne)／T／Ne]x100％．therelationshipbetweenT／Ne、T／Nd、砒％andresponseofchemotherapy,clinicalfactorandresponseofchemotherapywereassessedbytheIndep
4、endent—SamplesTTestforstatisticalanalysis．Probabilityvalues<0．05wereconsideredsignificant．Results1．Treatmenteffectsoffourcisplatin=basedregimell$foradvancedNSCLC(1)Overallresponserate(ORR)were34．9％．squamouscarcinomaandadenocarcinoma’SORRwere38．3％and30．6％,respe
5、ctively．InTP、GP、NP、DPregimen’sgroups，squamouscarcinoma’SORRwere41．7％、44．O％、34．8％、31．8％，mediansurvivaltime(MST)were12．1、12．3、11．7、11．8months，Timetoprogression(TTP)were4．4、4．5、3．1、4．4months，1-yearsurvivalratewere45．O％、44．0％、34．9％、36．4％respectively；adenocarcinoma
6、’SORRwere27．8％、25．O％、40．O％、28．6％，MSTwere11．2、11．1、11．5、10．4months；TIPwere3．7、3．2、4．0、4．7months，1-yearsurvivalratewere33．3％、30．O％、35．O％、35．7％respectively．ORR、MST、TTP、1-yearsurvivalratehaven’tsignificantdifferencesintwogroups(P>O．05)．Differentclinicalstageanddif
7、ferentclinicalfactorcouldn’tinfluencetreatmenteffects．(胗0．05)．(2)Themajoradversereactionsweremyelo—suppression、nausea、vomiting、phlebitis、alopecia．Therewerehi業(yè)estincidenceofthrombocytopenia(51．1％)inGPcomparedtoothergroups，especiallyIII。、IV。thrombocytopenia(24．4
8、％)inGP(P<0．05)．Theincidenceofnausea、vomitinginNP(37．2％)issignificanthigherthanothers(P
